Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

In-Press Preview

  • 2,583 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 258
  • 259
  • Next →
Cellular senescence mediates facioscapulohumeral muscular dystrophy
Usuk Jung, Erdong Wei, Ana Mitanoska, Philipp Heher, Kenric Chen, Haseeb Ahsan, Xu Zhang, Giorgio Tasca, Paul D. Robbins, Nathan K. LeBrasseur, Michael Kyba, Darko Bosnakovski
Usuk Jung, Erdong Wei, Ana Mitanoska, Philipp Heher, Kenric Chen, Haseeb Ahsan, Xu Zhang, Giorgio Tasca, Paul D. Robbins, Nathan K. LeBrasseur, Michael Kyba, Darko Bosnakovski
View: Text | PDF

Cellular senescence mediates facioscapulohumeral muscular dystrophy

  • Text
  • PDF
Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is driven by aberrant expression of the early embryonic transcription factor Double Homeobox 4 (DUX4), yet the mechanisms linking low, sporadic DUX4 activity to progressive muscle degeneration remain unclear. Here, we identify cellular senescence as a central and early mechanism in FSHD pathogenesis. Analysis of patient muscle transcriptomes revealed strong enrichment of senescence and senescence-associated secretory phenotype (SASP) programs that correlated with DUX4 activity, clinical severity, and histopathological changes. Notably, these signatures were detectable even in STIR-negative muscles, defining a prodystrophic state characterized by early molecular alterations preceding overt MRI-detectable inflammation and highlighting their potential utility as early biomarkers of disease activity. Using an FSHD mouse model, we show that DUX4-induced muscle injury rapidly triggers senescence, which then progressively expands. Fibroadipogenic progenitors and macrophages emerged as the principal senescent populations and key sources of pro-inflammatory and profibrotic SASP signals. Importantly, senescence was therapeutically modifiable. Treatment with the nucleoside reverse transcriptase inhibitor lamivudine (3TC), which inhibits LINE-1 reverse transcriptase activity, significantly reduced senescence, inflammation, and fibrosis while promoting muscle regeneration. These findings identify cellular senescence as a tractable driver of FSHD and warrant senotherapeutic strategies, particularly lamivudine, for clinical intervention in FSHD.

Authors

Usuk Jung, Erdong Wei, Ana Mitanoska, Philipp Heher, Kenric Chen, Haseeb Ahsan, Xu Zhang, Giorgio Tasca, Paul D. Robbins, Nathan K. LeBrasseur, Michael Kyba, Darko Bosnakovski

×

Decidua-accumulated effector-like memory CD8+ T cells orchestrate localized antimicrobial defense without compromising fetal tolerance
Lu Liu, Xixi Huang, Tingxuan Yin, Xianyang Hu, Hailin Yu, Guohua Zhu, Chunfang Xu, Jiajia Chen, Jiangyuan Du, Hongyan Wang, Qingyu Wu, Wei Zhang, Feng Wang, Huimei Wu, Meirong Du
Lu Liu, Xixi Huang, Tingxuan Yin, Xianyang Hu, Hailin Yu, Guohua Zhu, Chunfang Xu, Jiajia Chen, Jiangyuan Du, Hongyan Wang, Qingyu Wu, Wei Zhang, Feng Wang, Huimei Wu, Meirong Du
View: Text | PDF

Decidua-accumulated effector-like memory CD8+ T cells orchestrate localized antimicrobial defense without compromising fetal tolerance

  • Text
  • PDF
Abstract

Deciphering immune privilege at the maternal-fetal interface is essential for understanding how reproductive success and host defense are simultaneously maintained. Decidualization, occurring within the specialized stromal tissue encapsulating the fetus and placenta, shapes local immune adaptation required for healthy pregnancy. Here, we identify a decidua-enriched effector-like memory CD8+ T cell subset marked by CD45RA in humans and CX3CR1 in mice. These cells preferentially accumulate in the decidua, which harbors a CX3CL1-dominant chemokine niche, and disruption of Cx3cr1 or uterine Cx3cl1 impaired their decidual recruitment and tissue localization. Human CD45RA+ and murine CX3CR1+ decidual memory CD8+ T cells shared conserved transcriptional and functional features, including enhanced cytotoxic potential and limited inflammatory cytokine production. Functionally, CX3CL1-mediated CD8+ T cell accumulation improved local control of prenatal Listeria monocytogenes infection and reduced infection-associated fetal loss. In contrast, fetal antigen-specific CD8+ T cell accumulation and fetal resorption occurred independently of uterine CX3CL1. Together, our findings define the maternal-fetal interface as an active immunological gatekeeper, that compartmentalizing CD8+ T cell-mediated antimicrobial adaptive immunity through the conserved CX3CL1-CX3CR1 axis, supporting pathogen-specific defense while preserving fetal tolerance.

Authors

Lu Liu, Xixi Huang, Tingxuan Yin, Xianyang Hu, Hailin Yu, Guohua Zhu, Chunfang Xu, Jiajia Chen, Jiangyuan Du, Hongyan Wang, Qingyu Wu, Wei Zhang, Feng Wang, Huimei Wu, Meirong Du

×

Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency
Zaiyang Zhang, Jingliang Zhang, Xiaoling Chen, Brody A. Deming, Shivam Kant, Purba Mandal, Harish Kothandaraman, Phillip J. SanMiguel, Manasi S. Halurkar, Akila D. Abeyaratna, Morgan J. Robinson, Iuliia Vitko, Ronald P. Gaykema, Chongli Yuan, Nadia A. Lanman, Matthew T. Tegtmeyer, Dan Wang, Guangping Gao, Riyi Shi, Edward Perez-Reyes, Yang Yang
Zaiyang Zhang, Jingliang Zhang, Xiaoling Chen, Brody A. Deming, Shivam Kant, Purba Mandal, Harish Kothandaraman, Phillip J. SanMiguel, Manasi S. Halurkar, Akila D. Abeyaratna, Morgan J. Robinson, Iuliia Vitko, Ronald P. Gaykema, Chongli Yuan, Nadia A. Lanman, Matthew T. Tegtmeyer, Dan Wang, Guangping Gao, Riyi Shi, Edward Perez-Reyes, Yang Yang
View: Text | PDF

Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency

  • Text
  • PDF
Abstract

Pathogenic SCN2A loss-of-function (LoF) variants can cause severe, refractory epilepsy with limited treatment options. Existing Scn2a-LoF mouse models exhibit few spontaneous seizures, limiting the dynamic range needed to assess therapeutic efficacy. We therefore generated gene-trap Scn2a-deficient mice on the seizure-prone DBA/2J background. These mice experienced hundreds of spontaneous absence seizures per day, characterized by concurrent behavioral arrest and EEG spike–wave discharges (SWDs). Partial restoration of Scn2a expression reduced seizure burden. Electrophysiological analysis revealed impaired action potential waveforms yet increased repetitive firing, alongside coordinated downregulation of voltage-gated potassium channel genes, potentially contributing to hyperexcitability. Given the broad potassium channel downregulation and prior efficacy of KCNA1 gene therapy in refractory seizure models, we selected KV1.1 as a potential therapeutic target and used a drug-controllable adeno-associated virus (AAV) to express human KCNA1. We found that this intervention normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice. Extending these findings to a human cell-based platform, AAV-mediated KCNA1 expression also reduced neuronal firing in human cortical organoids carrying a SCN2A-truncating variant identified in patients. Together, these findings provide proof of principle for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants.

Authors

Zaiyang Zhang, Jingliang Zhang, Xiaoling Chen, Brody A. Deming, Shivam Kant, Purba Mandal, Harish Kothandaraman, Phillip J. SanMiguel, Manasi S. Halurkar, Akila D. Abeyaratna, Morgan J. Robinson, Iuliia Vitko, Ronald P. Gaykema, Chongli Yuan, Nadia A. Lanman, Matthew T. Tegtmeyer, Dan Wang, Guangping Gao, Riyi Shi, Edward Perez-Reyes, Yang Yang

×

Synthetic immunological niche reveals early immune dysregulation and stratifies therapeutic response in type 1 diabetes
Jyotirmoy Roy, Yifei Jiang, Runbo Mao, Jessica L. King, Amod Talekar, Donglin Liu, Lillian Holman, Haoxuan Zeng, Xin Luo, Laila M. Rad, Peter Sajjakulnukit, Brianna Ha, Kai Liu, Elizabeth J. Bealer, Bryan Wonski, Kathryn Kang, Sean T. Carey, Luke F. Bugada, Brooke M. Smiley, Shahzad Sohail, Antonio D. Holmes, Dominik Awad, Aaron H. Morris, Costas A. Lyssiotis, Jie Liu, Lonnie D. Shea
Jyotirmoy Roy, Yifei Jiang, Runbo Mao, Jessica L. King, Amod Talekar, Donglin Liu, Lillian Holman, Haoxuan Zeng, Xin Luo, Laila M. Rad, Peter Sajjakulnukit, Brianna Ha, Kai Liu, Elizabeth J. Bealer, Bryan Wonski, Kathryn Kang, Sean T. Carey, Luke F. Bugada, Brooke M. Smiley, Shahzad Sohail, Antonio D. Holmes, Dominik Awad, Aaron H. Morris, Costas A. Lyssiotis, Jie Liu, Lonnie D. Shea
View: Text | PDF

Synthetic immunological niche reveals early immune dysregulation and stratifies therapeutic response in type 1 diabetes

  • Text
  • PDF
Abstract

In Type 1 Diabetes (T1D), disease onset and immunotherapy responses vary widely, reflecting heterogeneous stage-specific immune dysregulation that remains undefined. To investigate this heterogeneity, we engineered microporous polycaprolactone scaffolds that form synthetic immunological niches (INs) subcutaneously and capture tissue-associated systemic immune changes. Building on our prior demonstration of IN-based longitudinal T1D monitoring, we use multimodal IN profiling to define the immune changes underlying divergent disease trajectories and immunotherapy responses. In non-obese diabetic (NOD) mice, longitudinal transcriptomic profiling of IN identified early myeloid associated changes, followed by increasing T cell-associated dysregulation that distinguished progressors from non-progressors. An early-stage IN-based T1D gene signature stratified NOD progressors from non-progressors by 6 weeks of age and was conserved across human T1D tissues, distinguishing T1D from non-diabetic individuals in spleen and pancreatic lymph node samples, but not in peripheral blood. Signature-based stratification revealed macrophage-associated TNFα pathway enrichment in pancreas of NOD progressors, which was validated in human T1D islets. Given the heterogeneous response to anti-TNFα therapy, IN profiling identified genesets associated with anti-TNFα efficacy and generated a response score that prospectively distinguished treatment-sensitive from resistant mice. These findings establish IN as a platform for detecting stage-wise immune dysregulation and stratifying immunotherapy response in T1D.

Authors

Jyotirmoy Roy, Yifei Jiang, Runbo Mao, Jessica L. King, Amod Talekar, Donglin Liu, Lillian Holman, Haoxuan Zeng, Xin Luo, Laila M. Rad, Peter Sajjakulnukit, Brianna Ha, Kai Liu, Elizabeth J. Bealer, Bryan Wonski, Kathryn Kang, Sean T. Carey, Luke F. Bugada, Brooke M. Smiley, Shahzad Sohail, Antonio D. Holmes, Dominik Awad, Aaron H. Morris, Costas A. Lyssiotis, Jie Liu, Lonnie D. Shea

×

Biological sex-dependent hormonal signaling and metabolomic profiles in obesity alter tumor microenvironment and immunotherapy outcomes
Logan V. Vick, Spencer R. Rosario, Ziming Wang, Craig Collins, Lam T. Khuat, Yatian Yang, Michael K. Sheng, Wahed A. Firoz, Ryan N. Nielsen, Yao-Hui Sun, Aryana M. Razmara, Hossein Borghaei, Emmanuel S. Antonarakis, Andrew Elliott, Nishant Gandhi, Raid Aljumaily, Sami Ibrahimi, Michael Machiorlatti, Sara K. Vesely, Shuchi Gulati, Sarbajit Mukherjee, Robert J. Canter, Sean J. Judge, Arta M. Monjazeb, William J. Murphy
Logan V. Vick, Spencer R. Rosario, Ziming Wang, Craig Collins, Lam T. Khuat, Yatian Yang, Michael K. Sheng, Wahed A. Firoz, Ryan N. Nielsen, Yao-Hui Sun, Aryana M. Razmara, Hossein Borghaei, Emmanuel S. Antonarakis, Andrew Elliott, Nishant Gandhi, Raid Aljumaily, Sami Ibrahimi, Michael Machiorlatti, Sara K. Vesely, Shuchi Gulati, Sarbajit Mukherjee, Robert J. Canter, Sean J. Judge, Arta M. Monjazeb, William J. Murphy
View: Text | PDF

Biological sex-dependent hormonal signaling and metabolomic profiles in obesity alter tumor microenvironment and immunotherapy outcomes

  • Text
  • PDF
Abstract

Commonly viewed as a negative prognostic factor in cancer, obesity is associated with improved responses to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Although data suggest a sexual dimorphism influencing the effects of obesity on immunotherapy responses, to our knowledge, the intersection of sex and obesity on immunotherapy requires further exploration. We demonstrate, in a pan-cancer analysis stratified by sex and BMI, that obesity (BMI ≥ 30) is associated with improved survival after ICI only in male patients. In preclinical models of diet-induced obesity (DIO), we observed that only DIO male tumor-bearing mice responded better to ICI. The differential effect of sex on outcomes was associated with alterations in the tumor microenvironment where DIO female mice demonstrated increased tumor-associated macrophages skewed toward a M2 phenotype. Ovariectomy of DIO female mice reduced M2 polarization and increased anti-tumor immune responses including increases in tumor-infiltrating T cells following ICI. Metabolomic analysis of DIO mice demonstrated distinct profiles base on sex. Re-stratification of female cancer patients revealed that obesity was associated with improved outcome, but only in post-menopausal (age ≥ 55) patients. We identify that the immunotherapy “obesity paradox” is sex-dependent and that hormonal and metabolomic status modulates the influence of obesity on ICIs.

Authors

Logan V. Vick, Spencer R. Rosario, Ziming Wang, Craig Collins, Lam T. Khuat, Yatian Yang, Michael K. Sheng, Wahed A. Firoz, Ryan N. Nielsen, Yao-Hui Sun, Aryana M. Razmara, Hossein Borghaei, Emmanuel S. Antonarakis, Andrew Elliott, Nishant Gandhi, Raid Aljumaily, Sami Ibrahimi, Michael Machiorlatti, Sara K. Vesely, Shuchi Gulati, Sarbajit Mukherjee, Robert J. Canter, Sean J. Judge, Arta M. Monjazeb, William J. Murphy

×

Attenuating NKG2D stimulation reshapes intratumoral NK cell functional state to enhance persistence and anti-tumor efficacy
Sizhe Liu, Ryan J. Brown, Payal Dhar, Geetha Priyanka Yerradoddi, Tyler A. Smith, Bin Zhang, Deyu Fang, Congcong He, David J. VanderWeele, Masha Kocherginsky, Arabela Grigorescu, Seth M. Pollack, Qingshu Meng, Qi Cao, Karla Guerra, Weiguo Cui, Jennifer D. Wu
Sizhe Liu, Ryan J. Brown, Payal Dhar, Geetha Priyanka Yerradoddi, Tyler A. Smith, Bin Zhang, Deyu Fang, Congcong He, David J. VanderWeele, Masha Kocherginsky, Arabela Grigorescu, Seth M. Pollack, Qingshu Meng, Qi Cao, Karla Guerra, Weiguo Cui, Jennifer D. Wu
View: Text | PDF

Attenuating NKG2D stimulation reshapes intratumoral NK cell functional state to enhance persistence and anti-tumor efficacy

  • Text
  • PDF
Abstract

NK cell-based therapies for solid tumors are limited by poor persistence and progressive functional impairment. Here, we investigated how the strength of NKG2D stimulation shapes NK cell fate and therapeutic efficacy. Using B10G5, a MICA/B-targeting partial agonist antibody that attenuates NKG2D stimulation, we show that reduced NKG2D stimulation reshapes the intratumoral NK cell compartment by enriching EOMEShiTCF1hi stem-like NK (stemNK) cell pool, preserving functional diversity, and limiting mitochondrial oxidative stress and exhaustion induced by chronic sMIC/MIC exposure. Mechanistically, we identified the H3K27me3 demethylase KDM6B as a conserved regulator of NK cell stemness whose enzymatic activity is required to maintain the intratumoral stemNK cell pool. Conversely, strong NKG2D stimulation induced mitochondrial ROS accumulation and upregulated the inhibitory receptor LAG3 on NK cells. Attenuated NKG2D stimulation on human NK cells increased KDM6B expression and reduced repressive H3K27me3 mark at the TCF7 locus. Importantly, attenuated NKG2D stimulation during ex vivo expansion enhanced human NK cell in vivo persistence and antitumor efficacy following adoptive transfer. Together, these findings establish NKG2D stimulation strength as a key determinant of NK cell fate and function in solid tumors and identify a translatable concept to improve NK cell-based immunotherapy for solid tumors.

Authors

Sizhe Liu, Ryan J. Brown, Payal Dhar, Geetha Priyanka Yerradoddi, Tyler A. Smith, Bin Zhang, Deyu Fang, Congcong He, David J. VanderWeele, Masha Kocherginsky, Arabela Grigorescu, Seth M. Pollack, Qingshu Meng, Qi Cao, Karla Guerra, Weiguo Cui, Jennifer D. Wu

×

Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program
Frederike Kramer, Merle Riedemann, Tsega-Ab Abera, Jessica Hem, Adela Herce, Anna E. Marneth, Benjamin Rolles, Maximilian Englert, Christian Hackenbroch, Mifra Faiz, Malvina Papanastasiou, Andrew H. Reiter, Steven A. Carr, Rong Li, Xintao Qiu, Gabriela S. Hobbs, Raghda Fouda, Olga Pozdnyakova, Masashi Miyauchi, Anna S. Nam, Ann Mullally
Frederike Kramer, Merle Riedemann, Tsega-Ab Abera, Jessica Hem, Adela Herce, Anna E. Marneth, Benjamin Rolles, Maximilian Englert, Christian Hackenbroch, Mifra Faiz, Malvina Papanastasiou, Andrew H. Reiter, Steven A. Carr, Rong Li, Xintao Qiu, Gabriela S. Hobbs, Raghda Fouda, Olga Pozdnyakova, Masashi Miyauchi, Anna S. Nam, Ann Mullally
View: Text | PDF

Mutant ASXL1 exacerbates CALR-mutant myeloproliferative neoplasms by enhancing a distinct megakaryocyte differentiation program

  • Text
  • PDF
Abstract

ASXL1 mutations confer a poor prognosis in myeloid neoplasms, including in CALR-mutated myeloproliferative neoplasms (MPN). We generated Calr-Asxl1 co-mutant mice and found more severe thrombocytosis and increased splenomegaly, compared with Calr single-mutant animals. Calr-Asxl1 co-mutant megakaryocytes displayed more pronounced morphological abnormalities and enhanced emperipolesis characteristic of inflammation. Concordant with this, a differentiation trajectory directly to megakaryocytes from hematopoietic stem cells (HSC) was more prominent in Calr-Asxl1 co-mutant mice. In this non-canonical trajectory, where megakaryocyte-biased HSCs directly differentiate into megakaryocyte progenitors, we found upregulation of Mef2c, a key transcriptional regulator of megakaryocyte lineage commitment. Mature Calr-Asxl1 co-mutant megakaryocytes displayed an enhanced proinflammatory transcriptional state, whereas the transcriptional signature of Calr-Asxl1 co-mutant HSCs was indicative of inflammation-resistance. Genotyping of transcriptomes (GoT) confirmed an activated megakaryocytic differentiation program in CALR-ASXL1 co-mutant HSCs in primary human MPN bone marrow. These findings link the enhanced severity of CALR-ASXL1 co-mutant MPN to altered megakaryocyte differentiation and help explain some of the biological basis for the more severe MPN phenotype observed in patients.

Authors

Frederike Kramer, Merle Riedemann, Tsega-Ab Abera, Jessica Hem, Adela Herce, Anna E. Marneth, Benjamin Rolles, Maximilian Englert, Christian Hackenbroch, Mifra Faiz, Malvina Papanastasiou, Andrew H. Reiter, Steven A. Carr, Rong Li, Xintao Qiu, Gabriela S. Hobbs, Raghda Fouda, Olga Pozdnyakova, Masashi Miyauchi, Anna S. Nam, Ann Mullally

×

HIV reservoir cells do not show general resistance to effector molecules secreted by cytolytic T lymphocytes
Niklas Bachmann, Bailey Kim, Francesco R. Simonetti, Colin M. Kovacs, Rebecca Hoh, Steven G. Deeks, Janet D. Siliciano, Robert F. Siliciano
Niklas Bachmann, Bailey Kim, Francesco R. Simonetti, Colin M. Kovacs, Rebecca Hoh, Steven G. Deeks, Janet D. Siliciano, Robert F. Siliciano
View: Text | PDF

HIV reservoir cells do not show general resistance to effector molecules secreted by cytolytic T lymphocytes

  • Text
  • PDF
Abstract

To eliminate the persistent reservoir of cells harboring intact HIV-1 proviruses in people living with HIV-1 (PLWH), cure strategies like the Shock-and-Kill approach rely on effector functions of cytolytic T lymphocytes (CTL). CTL are involved in the initial control of HIV-1 viremia and target productively infected cells throughout the course of infection. However, selective killing of susceptible cells could generate a reservoir dominated by cells with dysregulated cell death pathways or other features conferring resistance to killing. Here, we use CTL-engaging single-chain diabodies to assess the rate of lysis of uninfected and HIV-1-infected primary CD4+ T cells under identical CTL pressure in the settings of both latent and active infection. Our findings indicate that with this mode of CTL triggering, infected and uninfected CD4+ T cells from PLWH on ART are generally lysed at identical rates, and that an apparent survival advantage for actively infected CD4+ T cells primarily reflects the reduced surface antigen availability through previously described Nef-dependent downregulation of MHC class I molecules. No survival advantage is observed when the CTL response is directed through diabodies to the stably expressed non-classical MHC class I molecule HLA-E, indicating equal susceptibility to cell death.

Authors

Niklas Bachmann, Bailey Kim, Francesco R. Simonetti, Colin M. Kovacs, Rebecca Hoh, Steven G. Deeks, Janet D. Siliciano, Robert F. Siliciano

×

Donor-derived CD8+CD122+ Tregs generated in mixed donor chimeric NOD mice suppress autoreactive T cells
Shiva Pathak, Cameron S. Bader, Bettina P. Iliopoulou, Shobha Regmi, Pin-I Chen, Biki Gupta, Xiangni Wu, Blake Mosher, Alexandra Wells, Levon Witherspoon, Kayla C. Jenkins, William Harper, Emily Y. SooHoo, Abigail Twoy, Rizwan Ahmed, Suparna Dutt, Nadine Nagy, Kent P. Jensen, C. Garrison Fathman, Avnesh S. Thakor, Mark M. Davis, Everett H. Meyer
Shiva Pathak, Cameron S. Bader, Bettina P. Iliopoulou, Shobha Regmi, Pin-I Chen, Biki Gupta, Xiangni Wu, Blake Mosher, Alexandra Wells, Levon Witherspoon, Kayla C. Jenkins, William Harper, Emily Y. SooHoo, Abigail Twoy, Rizwan Ahmed, Suparna Dutt, Nadine Nagy, Kent P. Jensen, C. Garrison Fathman, Avnesh S. Thakor, Mark M. Davis, Everett H. Meyer
View: Text | PDF

Donor-derived CD8+CD122+ Tregs generated in mixed donor chimeric NOD mice suppress autoreactive T cells

  • Text
  • PDF
Abstract

The establishment of mixed hematopoietic chimerism is a promising way to induce immune tolerance for islet replacement therapy and to treat the underlying autoimmunity in type 1 diabetes (T1D). Mixed chimerism not only promotes effective thymic negative selection of autoreactive cells but also restores regulatory T cell (Treg) function and peripheral tolerance. In the current study, we determined that a novel class of donor-derived CD8+CD44+CD122+ Tregs (d-CD8+CD122+ Tregs) plays a crucial role in controlling autoimmunity in non-obese diabetic (NOD) mice with induced mixed chimerism. Using adoptive T cell transfer experiments, we showed that d-CD8+CD122+ Tregs abrogate autoimmunity by suppressing the exogenously injected diabetogenic T cells in Recombination-Activating Gene deficient NOD mice. These d-CD8+CD122+ Tregs from NOD chimeras show upregulation of Helios, Programmed cell death protein 1, perforin, granzyme-B, CD39, Folate receptor 4, and downregulation of proinflammatory marker SCART1. Using in vitro assays, we show that d-CD8+CD122+ Tregs respond specifically to a Complementarity-Determining Region-3 peptide sequence derived from T cell receptors of islet antigen-specific autoreactive T cells. Similarly, we found that individuals with T1D have a deficiency in CD8+CD122+ Tregs, suggesting a potential loss of regulatory function accompanies disease onset. Revitalizing CD8+CD122+ Tregs may offer a new therapeutic strategy of restoring immune tolerance in autoimmune diabetes.

Authors

Shiva Pathak, Cameron S. Bader, Bettina P. Iliopoulou, Shobha Regmi, Pin-I Chen, Biki Gupta, Xiangni Wu, Blake Mosher, Alexandra Wells, Levon Witherspoon, Kayla C. Jenkins, William Harper, Emily Y. SooHoo, Abigail Twoy, Rizwan Ahmed, Suparna Dutt, Nadine Nagy, Kent P. Jensen, C. Garrison Fathman, Avnesh S. Thakor, Mark M. Davis, Everett H. Meyer

×

Metformin Preserves Regional Brain Glucose Uptake, Structure, and Functional Connectivity in Adults with Insulin Resistance
Mark W. Pataky, Gregory N. Ruegsegger, Hang Joon Jo, Katherine A. Klaus, Kyle J. Sevits, Robert G. Leija, Arathi Prabha Kumar, Seokbeen Lim, Sumaiya Sinhawansa, Rickey E Carter, Nikki H. Stricker, Val J. Lowe, John D. Port, K. Sreekumaran Nair
Mark W. Pataky, Gregory N. Ruegsegger, Hang Joon Jo, Katherine A. Klaus, Kyle J. Sevits, Robert G. Leija, Arathi Prabha Kumar, Seokbeen Lim, Sumaiya Sinhawansa, Rickey E Carter, Nikki H. Stricker, Val J. Lowe, John D. Port, K. Sreekumaran Nair
View: Text | PDF

Metformin Preserves Regional Brain Glucose Uptake, Structure, and Functional Connectivity in Adults with Insulin Resistance

  • Text
  • PDF
Abstract

BACKGROUND. Dementia is a rapidly expanding public health problem with major socio-economic burden. Insulin resistance (IR) is a prevalent but modifiable risk factor for dementia, yet its effects on brain structure, functional connectivity, and metabolism remain incompletely understood. METHODS. Regional brain glucose uptake (PET), volumes (MRI), functional connectivity (fMRI), and cognition (NIH Toolbox) was measured in 72 adults with or without markers of IR. To evaluate reversibility of IR-associated brain deficits, forty older adults with IR were randomized to forty weeks of metformin or placebo, and brain measures were repeated. As a proof-of-concept experiment, we developed a conditional brain-specific insulin receptor knockout mouse and assessed brain mitochondrial function and cognition. RESULTS. In older adults with markers of IR is associated with diminished total and regional brain volumes in areas critical for neuronal connectivity, memory, and learning, including cerebral white matter and the hippocampus. Reduced functional connectivity between brain regions detrimental for cognition was also noted. Further, we demonstrated that ATP production, essential for neuronal connectivity, was diminished in neuron-specific insulin receptor knockout mice accompanied by deficits in hippocampal- and prefrontal-dependent tasks. Forty weeks of metformin improved systemic insulin sensitivity concurrent to preserved brain glucose uptake, volume, and functional connectivity within specific regions central to decision-making and learning. Metformin was also associated with an improved composite measure of processing speed and working memory. CONCLUSION. These findings highlight IR as a key regulator of brain metabolism and support the concept that insulin sensitization can prevent neurobiological deficits in older people with IR.

Authors

Mark W. Pataky, Gregory N. Ruegsegger, Hang Joon Jo, Katherine A. Klaus, Kyle J. Sevits, Robert G. Leija, Arathi Prabha Kumar, Seokbeen Lim, Sumaiya Sinhawansa, Rickey E Carter, Nikki H. Stricker, Val J. Lowe, John D. Port, K. Sreekumaran Nair

×
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 258
  • 259
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts